BioMarin (BMRN): Valuation Insights After Revenue Upside and PALYNZIQ Expansion News [Yahoo! Finance]
BioMarin Pharmaceutical Inc. (BMRN)
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.biomarin.com
Company Research
Source: Yahoo! Finance
This reflects commercial momentum in key therapeutic areas. The FDA's acceptance of a supplemental Biologics License Application for PALYNZIQ to include adolescents with PKU also marks an important regulatory milestone. This could further expand BioMarin's addressable market. See our latest analysis for BioMarin Pharmaceutical. BioMarin Pharmaceutical's recent positive news has yet to spark a turnaround in its stock, with the share price ending at $52.85 after a challenging run. Its year-to-date share price return is down 20.5%, and the one-year total shareholder return sits at -19.9%. Despite short-term commercial wins and pipeline progress, investor sentiment has been cautious, and broader momentum is still searching for a foothold after several quarters of underperformance. If you're interested in what else is happening in healthcare, take the next step and explore See the full list for free. With the stock still trading well below analyst price targets despite improving
Show less
Read more
Impact Snapshot
Event Time:
BMRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMRN alerts
High impacting BioMarin Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
BMRN
News
- BioMarin Pharmaceutical Inc. (BMRN): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- BioMarin Pharmaceutical (NASDAQ:BMRN) had its "market perform" rating reaffirmed by analysts at Leerink Partners. They now have a $60.00 price target on the stock, down previously from $82.00.MarketBeat
- BioMarin Pharmaceutical (BMRN): Evaluating Valuation After Raised Guidance on Revenue Strength [Yahoo! Finance]Yahoo! Finance
- BioMarin Pharmaceutical (NASDAQ:BMRN) had its "sell (d)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- 2 Reasons to Like BMRN and 1 to Stay Skeptical [Yahoo! Finance]Yahoo! Finance
BMRN
Earnings
- 10/27/25 - Miss
BMRN
Sec Filings
- 12/2/25 - Form 4
- 11/14/25 - Form SCHEDULE
- 10/28/25 - Form 10-Q
- BMRN's page on the SEC website